Berlin, Germany — Patients with weakened immune systems or those about to begin immunosuppressive treatments now face clearer guidance on how to assess their risk of latent tuberculosis infection (LTBI), thanks to updated recommendations from France’s Haute Autorité de Santé (HAS). The revised protocol, published in [June 2024](https://www.has-sante.fr/upload/docs/application/pdf/2024-06/avis_igra_2024.pdf) and effective immediately, expands the use of interferon-gamma release assays (IGRA) in high-risk groups—a shift that could reshape tuberculosis (TB) screening practices across Europe.
For decades, IGRA tests have been the gold standard for detecting LTBI, offering higher specificity than traditional tuberculin skin tests (TST). Yet their application in immunocompromised patients has been controversial, given the risk of false negatives due to impaired immune responses. The HAS’s latest update—endorsed by infectious disease specialists and public health bodies—aims to harmonize testing protocols for patients with HIV, organ transplants, or autoimmune conditions before starting drugs like methotrexate or biologics. The stakes are high: untreated LTBI can progress to active TB, a leading cause of death worldwide.
“This is a significant step forward,” says Dr. Marie-Laure Chaix, a Paris-based infectious disease physician and member of the Société de Pathologie Infectieuse de Langue Française (SPILF). “Immunocompromised patients were often overlooked in LTBI screening because their immune systems might not react strongly to IGRA antigens. Now, we have clearer criteria to identify who should be tested—and when.”
Why the Update Matters: Key Changes in the HAS Guidelines
The HAS’s revised recommendations address three critical gaps in current practice:
- Broader eligibility: IGRA tests are now recommended for all patients with moderate-to-severe immunosuppression—previously, some subgroups (e.g., those on low-dose corticosteroids) were excluded due to uncertain test accuracy. The update aligns with WHO’s 2023 LTBI guidelines, which emphasize risk-based screening over rigid criteria.
- Timing adjustments: Testing should occur before starting immunosuppressive therapy, not after. The HAS notes that “delayed screening increases the window for undiagnosed LTBI activation,” particularly in patients with HIV/AIDS or post-transplant recipients.
- Combined testing strategies: In cases of equivocal IGRA results, the HAS now permits supplementary quantiferon-TB Gold or T-SPOT.TB assays, with clinical judgment guiding follow-up chest X-rays or sputum cultures.
Who Is Affected? High-Risk Groups and Practical Implications
The guidelines directly impact:
- Patients with autoimmune diseases (e.g., rheumatoid arthritis, lupus) starting biologic DMARDs like adalimumab or tocilizumab. A 2023 study in The Lancet Rheumatology found that 12% of untreated LTBI cases progressed to active TB within 12 months of immunosuppression.
- Solid-organ transplant recipients, who face a 10–20% lifetime risk of TB reactivation if LTBI goes undetected. The HAS emphasizes pre-transplant IGRA screening as non-negotiable.
- People living with HIV, where LTBI prevalence can exceed 30% in high-burden countries. The update clarifies that IGRA tests should be repeated annually for those on antiretroviral therapy (ART) with CD4 counts <200 cells/µL.
How IGRA Tests Work: A Primer for Patients and Clinicians
Unlike the PPD skin test, which can yield false positives due to BCG vaccination or environmental mycobacteria, IGRA tests measure the immune response to Mycobacterium tuberculosis-specific antigens (ESAT-6 and CFP-10). The process involves:
- A blood draw to isolate white blood cells.
- Exposure of cells to TB antigens in a lab setting.
- Measurement of interferon-gamma release via ELISA or enzyme-linked immunosorbent assay.
- Results interpreted as positive, negative, or indeterminate (if the immune response is too weak).
Critical note: Indeterminate IGRA results—common in advanced HIV or post-chemotherapy patients—now trigger a mandatory risk assessment by an infectious disease specialist, per the HAS. This may include:
- Repeat IGRA testing after immune recovery (e.g., 3–6 months post-HIV viral suppression).
- Empirical LTBI treatment (e.g., rifampicin + isoniazid for 3 months) if the clinical risk is deemed high.
- Consultation with a pulmonologist for advanced imaging.
Global Context: How France’s Update Compares to Other Countries
France’s HAS is not alone in refining LTBI screening protocols. Recent policy shifts include:
| Country/Region | Key Guideline Change | Effective Date | Source |
|---|---|---|---|
| United States (CDC) | Expanded IGRA use in HIV patients with CD4 counts >200 cells/µL; discontinued routine TST for BCG-vaccinated immigrants. | March 2023 | CDC LTBI Guidelines |
| United Kingdom (NICE) | Recommended IGRA as first-line test for all LTBI screening, including pre-transplant evaluations. | October 2022 | NICE NG33 |
| World Health Organization | Endorsed targeted IGRA testing in high-risk groups, with emphasis on programmatic management. | March 2023 | WHO LTBI Guidelines |
France’s update stands out for its pre-emptive focus—prioritizing testing before immunosuppression begins, rather than reactively. “This is a proactive approach,” explains Dr. Fischer. “Many other countries still rely on post-treatment screening, which misses the window to prevent TB activation.”
What Happens Next? Monitoring and Implementation
The HAS’s recommendations will be rolled out in phases:
- July–September 2024: Training sessions for French infectious disease specialists and pulmonologists, coordinated by the SPILF and Société de Pneumologie de Langue Française (SPLF).
- October 2024: Integration into national health insurance reimbursement codes for IGRA tests in high-risk groups.
- 2025: Expected publication of a companion document addressing cost-effectiveness and regional disparities in access.
For patients and clinicians outside France, the HAS’s update serves as a blueprint for risk-stratified LTBI screening. “The trend is clear,” says Dr. Fischer. “Countries are moving away from one-size-fits-all approaches toward personalized, pre-emptive strategies—especially for populations where TB reactivation carries the highest mortality.”
Key Takeaways: What You Need to Remember
- IGRA tests are now recommended for all immunocompromised patients before starting immunosuppressive drugs, not just those with severe conditions.
- Indeterminate results require a multidisciplinary risk assessment, including repeat testing or empirical treatment.
- Timing is critical: Screen before immunosuppression begins to prevent TB activation.
- Combined strategies (IGRA + clinical judgment) improve accuracy in equivocal cases.
- Global alignment: France’s update reflects broader trends toward targeted, high-risk LTBI screening.
Frequently Asked Questions
Q: Are IGRA tests covered by insurance in France?
Yes, but coverage depends on the patient’s condition. The HAS update will expand reimbursement for high-risk groups (e.g., pre-transplant, HIV with CD4 <200) starting October 2024. Patients should verify with their Assurance Maladie provider.
Q: Can IGRA tests replace chest X-rays for LTBI screening?
No. The HAS guidelines state that IGRA tests supplement clinical evaluation. Chest X-rays remain essential for ruling out active TB, especially in patients with symptoms like persistent cough or night sweats.
Q: What if my IGRA test is negative but I’m still at high risk?
A negative IGRA does not rule out LTBI in immunocompromised patients. The HAS recommends repeating the test after immune recovery or considering prophylactic treatment based on clinical risk factors.
Next Steps: The HAS will publish a detailed implementation roadmap by October 15, 2024, including regional workshops. For the latest updates, monitor the HAS website or consult your infectious disease specialist.
Have questions about LTBI screening or the new guidelines? Share your experiences or concerns in the comments below—or tag @WorldTodayJrnl on X/Twitter for further discussion.